鲁索替尼乳膏的效果怎么样？

JAK inhibitors (JAKs) approved by the U.S. Food and Drug Administration (FDA) include Tofacitinib and Ruxolitinib, which are mainly used for the treatment of rheumatoid arthritis, myelofibrosis and polycythemia vera. It is the first and only topical formulation of a JAK inhibitor in the United States (FDA). In addition to being suitable for vitiligo, the FDA has also approved Opzelura cream for short-term or non-sustained chronic treatment of patients with mild to moderate atopic dermatitis (AD). The treatment success rate and safety are good. So, how effective is ruxolitinib cream?

ruxolitinib cream effects

The U.S. FDA's approval of ruxolitinib was based on data from the TRuE-AD project, which included two randomized, vehicle-controlled, pivotal Phase 3 studies of TRuE-AD2 and TRuE-AD1 with the same design. The trial included more than 1,200 adolescent and adult patients with mild to moderate AD. Clinical trial results showed that compared with vehicle, patients treated with ruxolitinib cream at different doses had a significantly better proportion of patients achieving the primary endpoint after 8 weeks of treatment than the control group. Ruxolitinib treatment significantly reduced AD-related skin inflammation and pruritus. Reducing itching can potentially improve disease progression and quality of life in patients with atopic dermatitis.

Ruxolitinib Cream Side Effects

Some include: diarrhea, bronchitis, ear infections, increased eosinophil (a type of white blood cell) count, folliculitis, tonsillitis, hives, pain or swelling in the nose or throat (nasopharyngitis), and runny nose. In addition, the drug also carries a black box warning, reminding patients that the use of JAK inhibitors to treat inflammation may cause serious infections, mortality, malignant tumors, major adverse cardiovascular events and thrombosis.

Recommended hot articles: